Evaluation of Side Effects of Mitotane

NCT00568139 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2026-05-07

No results posted yet for this study

Summary

Mitotane is standard therapy in the treatment of adrenocortical carcinoma. However, many adverse effects are not well documented. Therefore, we are aiming at collecting data about adverse effects in patients treated with mitotane

Conditions

  • Adrenocortical Carcinoma

Sponsors & Collaborators

  • University of Wuerzburg

    lead OTHER

Principal Investigators

  • Martin Fassnacht, MD · University of Wuerzburg

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2027-12-31
Completion
2029-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00568139 on ClinicalTrials.gov